Alliancebernstein L.P. grew its holdings in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 19.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 109,296 shares of the biotechnology company’s stock after purchasing an additional 17,800 shares during the quarter. Alliancebernstein L.P. owned about 0.15% of Momenta Pharmaceuticals worth $1,847,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the company. Wells Fargo & Company MN grew its position in shares of Momenta Pharmaceuticals by 6.1% in the second quarter. Wells Fargo & Company MN now owns 205,599 shares of the biotechnology company’s stock valued at $3,475,000 after purchasing an additional 11,789 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Momenta Pharmaceuticals by 1.6% in the second quarter. JPMorgan Chase & Co. now owns 647,017 shares of the biotechnology company’s stock valued at $10,934,000 after purchasing an additional 10,273 shares during the last quarter. State of Tennessee Treasury Department grew its position in shares of Momenta Pharmaceuticals by 6.0% in the second quarter. State of Tennessee Treasury Department now owns 62,491 shares of the biotechnology company’s stock valued at $1,056,000 after purchasing an additional 3,510 shares during the last quarter. Swiss National Bank grew its position in shares of Momenta Pharmaceuticals by 5.1% in the second quarter. Swiss National Bank now owns 115,700 shares of the biotechnology company’s stock valued at $1,955,000 after purchasing an additional 5,600 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of Momenta Pharmaceuticals by 4.9% in the second quarter. Principal Financial Group Inc. now owns 541,686 shares of the biotechnology company’s stock valued at $9,154,000 after purchasing an additional 25,144 shares during the last quarter. 93.88% of the stock is currently owned by institutional investors.

Shares of Momenta Pharmaceuticals, Inc. (MNTA) opened at 14.35 on Thursday. Momenta Pharmaceuticals, Inc. has a 1-year low of $10.75 and a 1-year high of $19.90. The company has a 50 day moving average of $16.11 and a 200 day moving average of $15.80. The company’s market cap is $1.06 billion.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The business had revenue of $23.57 million for the quarter, compared to analyst estimates of $24.64 million. During the same quarter in the prior year, the business earned ($0.31) EPS. Momenta Pharmaceuticals’s quarterly revenue was down 10.8% on a year-over-year basis. Equities analysts expect that Momenta Pharmaceuticals, Inc. will post ($1.50) earnings per share for the current fiscal year.

Several equities research analysts have recently issued reports on the company. Zacks Investment Research downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Robert W. Baird downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price target for the company from $22.00 to $15.00 in a research report on Friday, October 6th. ValuEngine downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. J P Morgan Chase & Co reaffirmed a “hold” rating and issued a $14.00 price target on shares of Momenta Pharmaceuticals in a research report on Thursday, October 5th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $14.00 price target (down from $18.00) on shares of Momenta Pharmaceuticals in a research report on Thursday, October 5th. Three analysts have rated the stock with a sell rating and nine have issued a hold rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $15.00.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/19/momenta-pharmaceuticals-inc-mnta-shares-bought-by-alliancebernstein-l-p.html.

In related news, President Craig A. Wheeler sold 16,953 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $16.94, for a total value of $287,183.82. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Craig A. Wheeler sold 35,667 shares of the company’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $19.03, for a total transaction of $678,743.01. Following the completion of the transaction, the president now owns 286,121 shares in the company, valued at approximately $5,444,882.63. The disclosure for this sale can be found here. In the last quarter, insiders sold 79,663 shares of company stock worth $1,414,498. 4.40% of the stock is owned by company insiders.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.